Renal Biobank and TARGET-KD
Summary
The TARGET-KD program (The Application of Renal Genomics to Enhance the Treatment of Kidney Disease) is seeking to recruit subjects who are scheduled to undergo a kidney biopsy in the near future who are willing to donate a one-time urine and blood sample to the kidney disease biobank at the University of Calgary. Samples will be de-identified and used in future studies in order to discover and validate disease-classifying molecular and genetic indicators that may exist in the blood and urine. These discoveries could lead to the development of simple urine or blood-based diagnostic tests rather than requiring an invasive kidney biopsy to diagnose patients and treat them appropriately. We are also actively recruiting healthy volunteers without kidney disease to donate urine and blood samples on a one-time basis to be used as controls for comparison studies.
Eligibility
Eligible ages: 0 to 100
Accepts healthy participants: Yes
Inclusion criteria:
Kidney disease patients:
a. Undergoing kidney biopsy procedure in Calgary
b. Patient or guardian (for patients <18 years of age) able to provide consent, medical information
Healthy Volunteers:
a. > 18 years of age
b. Willing to complete a 10-15 minute study visit at the University of Calgary
c. Willing to disclose smoking status, prior medical complications, medications
d. Can provide Alberta Provincial health card number
Exclusion criteria:
Kidney disease patients:
a. Unable to consent, fully disclose medical information
Healthy Volunteers:
a. < 18 years of age
b. Any systemic or chronic disease history
c. Unable to fully disclose smoking status, prior medical complications, medications
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
If you would like to learn more, please visit https://www.target-kd.com or contact Graciela Andonegui at 403-210-7097 or andonegu@ucalgary.ca
Principal investigator:
Daniel Abraham Muruve
Clinical trial:
No
REB-ID:
REB17-0639
External links